Myomo Inc. filings document material events for a Delaware medical-device company focused on wearable robotics and the MyoPro powered upper-limb orthosis. Recent Form 8-K disclosures furnish quarterly and annual operating results, revenue sources, MyoPro orders and authorizations, patient-pipeline activity, and exhibits tied to financial press releases.
The filing record also covers governance and capital-structure matters, including board appointments, director compensation arrangements, indemnification agreements, and loan and security agreements. These disclosures describe formal reporting of operating performance, financing terms, corporate governance actions and related risk and control subjects for MYO.
MYOMO, INC. Chief Medical Officer Harry Kovelman reported open-market sales of company common stock over two days. He sold 20,464 shares on May 27, 2026 at a weighted average price of $1.002 per share and 11,536 shares on May 28, 2026 at a weighted average price of $1.0172 per share. After these transactions, he continued to hold 108,618 shares directly.
MYOMO, INC. officer Harry Kovelman reported a proposed sale of 11,536 common shares, with an aggregate market value of $11,734.42 and an approximate sale date of May 28, 2026. The shares were acquired from the issuer as restricted stock on June 28, 2025. During the prior three months, Harry Kovelman sold 20,464 common shares on May 27, 2026, for gross proceeds of $20,468.09.
MYOMO, INC. (MYO) reports a proposed sale for its officer, Harry Franklin Kovelman, of 20,464 common shares with an aggregate market value of $20,468.09. The approximate sale date is May 27, 2026, and Morgan Stanley Smith Barney LLC is named as broker. The listed prior acquisitions are restricted stock from the issuer dated June 28, 2024, through June 28, 2025.
MYOMO, INC. director F. Thomas Kirk reported two open-market purchases of common stock. On May 15, 2026, he bought 31,605 shares at a weighted average price of $0.9096 per share, in multiple lots priced between $0.815 and $0.91.
On May 18, 2026, he bought an additional 43,401 shares at a weighted average price of $0.91 per share, with individual trades between $0.9041 and $0.91. After these purchases, he directly owns 628,863 common shares.
Myomo, Inc. received an amended Schedule 13D from Horton Capital entities and Joseph M. Manko Jr., disclosing beneficial ownership of 2,309,775 common shares, or about 6.0% of the company based on 38,638,653 shares outstanding as of May 1, 2026.
The shares, held through Horton Capital Partners Fund, were bought in open-market transactions for an aggregate purchase price of about $3.6 million. Manko was appointed to Myomo’s board of directors effective May 9, 2026, to serve until the 2027 annual meeting.
Horton Capital submitted a shareholder proposal for the 2026 proxy asking Myomo to declassify its board so all directors stand for annual election. The filing notes the group may continue to engage with management and other shareholders and could increase or decrease its stake over time.
MYOMO, INC. director Joseph M. Manko Jr., through Horton Capital Partners Fund, LP, reported net open-market purchases of 201,197 MYO shares. The fund bought 170,830 shares at an average price of $0.8602 per share on May 14, 2026, and 30,367 shares at $0.8878 per share on May 15, 2026. Following these indirect transactions, the fund’s reported MYO holdings rose to 2,309,775 shares.
MYOMO, INC. director Joseph M. Manko Jr. filed an initial Form 3 reporting his beneficial ownership in the company. The filing shows indirect ownership of 2,108,578 MYO shares, held through Horton Capital Partners Fund, LP, reflecting his existing stake rather than a new transaction.
MYOMO, INC. Chief Commercial Officer Micah Mitchell reported an open-market sale of 90,231 shares of common stock on May 14. The weighted average sale price was $0.861 per share, with individual trades executed between $0.85 and $0.889 per share. After these transactions, Mitchell directly owns 109,478 shares of Myomo common stock.
MYO filed a Form 144 reporting a proposed sale of 90,231 shares of Common Stock by Morgan Stanley Smith Barney LLC Executive Financial Services. The submission lists multiple tranches of restricted stock dated 06/05/2024, 06/07/2024, 06/28/2024, 03/11/2025, 06/05/2025, and 06/28/2025.
The form provides per‑tranche counts (for example, 24,500 shares on 06/28/2024 and 40,000 shares on 06/28/2025) and names the selling broker. Timing and sale mechanics beyond the listed dates are not detailed in the excerpt.